Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted drug tested for Tough-to-Treat lung cancer

NCT ID NCT05513703

Terminated Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental drug called telisotuzumab vedotin for adults with advanced non-small cell lung cancer that has a specific genetic feature called MET amplification. The goal was to see if the drug could shrink tumors and control the cancer. The trial was terminated early after enrolling only 9 participants, so its full results are unknown.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asklepios Fachkliniken Muenchen-Gauting /ID# 248082

    Gauting, 82131, Germany

  • CHU Lille - Hôpital Albert Calmette /ID# 246263

    Lille, Hauts-de-France, 59037, France

  • Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671

    Los Alamitos, California, 90720-3309, United States

  • Centre Jean Perrin /ID# 246268

    Clermont-Ferrand, 63011, France

  • Chungbuk National University Hospital /ID# 248405

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Duplicate_Fondazione IRCCS San Gerardo dei Tintori /ID# 247584

    Monza, Monza E Brianza, 20900, Italy

  • Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 250714

    Fukuoka, Fukuoka, 811-1395, Japan

  • Hadassah Medical Center-Hebrew University /ID# 243298

    Jerusalem, Jerusalem, 91120, Israel

  • Hokkaido University Hospital /ID# 250316

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267

    Bron, Rhone, 69500, France

  • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 247585

    Rome, 00144, Italy

  • Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 248329

    Candiolo, Torino, 10060, Italy

  • Kaohsiung Chang Gung Memorial Hospital /ID# 248143

    Kaohsiung City, Kaohsiung, 833, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 248144

    Kaohsiung City, 807, Taiwan

  • Keimyung University Dongsan Hospital /ID# 247371

    Daegu, Gyeongsangbuk-do, 42601, South Korea

  • Linkou Chang Gung Memorial Hospital /ID# 248145

    Taoyuan, 333, Taiwan

  • Meir Medical Center /ID# 243208

    Kfar Saba, Central District, 4428164, Israel

  • Monash Health - Monash Medical Centre /ID# 247679

    Clayton, Victoria, 3168, Australia

  • National Cancer Center Hospital /ID# 250319

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 250317

    Kashiwa-shi, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital /ID# 248142

    Tainan, 704, Taiwan

  • Osaka International Cancer Institute /ID# 251507

    Osaka, Osaka, 541-8567, Japan

  • Pusan National University Yangsan Hospital /ID# 248489

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Rabin Medical Center /ID# 248631

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus /ID# 246781

    Haifa, H_efa, 3109601, Israel

  • Samsung Medical Center /ID# 248407

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Shizuoka Cancer Center /ID# 251752

    Sunto-gun, Shizuoka, 411-8777, Japan

  • The Chaim Sheba Medical Center /ID# 243207

    Ramat Gan, Tel Aviv, 5265601, Israel

  • Valley Medical Center /ID# 251880

    Renton, Washington, 98055-5738, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER